| Sep 15 |
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
|
| Sep 13 |
AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'
|
| Sep 13 |
AstraZeneca, Roche cut at Deutsche after trial readouts for key drugs
|
| Sep 13 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
|
| Sep 13 |
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
|
| Sep 12 |
AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
|
| Sep 11 |
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
|
| Sep 11 |
Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout
|
| Sep 10 |
AstraZeneca PLC (AZN): Short Seller Sentiment For This Big-Name Stock is Bullish
|
| Sep 10 |
AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients
|
